Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Real-time Estimate Cboe BZX Other stock markets 03:07:22 2024-04-30 pm EDT			5-day change	1st Jan Change
5.275 ^USD	-1.77%		-3.66%	-48.08%

Mar. 13	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Feb. 29	Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	Apr. 22	GL
Editas Medicine : April 2024 Corporate Presentation	Apr. 11	PU
Editas Medicine : Corporate Effectiveness Report April 2024	Apr. 11	PU
Editas: Q4 Earnings Snapshot	Feb. 28	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	Feb. 28	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	Feb. 28	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	Feb. 21	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	Feb. 21	AQ
Editas Medicine to Participate in Upcoming Investor Conferences	Jan. 31	GL
Editas Medicine to Participate in Upcoming Investor Conferences	Jan. 31	AQ
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	Jan. 08	GL
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	Jan. 08	AQ
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	Dec. 13	GL
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	Dec. 13	AQ
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar	Dec. 11	GL
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar	Dec. 11	AQ
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 13	AQ
Editas: Q3 Earnings Snapshot	Nov. 03	AQ
Editas Medicine Announces Third Quarter 2023 Results and Business Updates	Nov. 03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Press Releases

Filters